​

Revance Therapeutics Ownership | Who Owns Revance Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Revance Therapeutics Ownership Summary

Revance Therapeutics is owned by 78.60% institutional investors, 8.52% insiders, and 12.88% retail investors. Blackrock is the largest institutional shareholder, holding 9.32% of RVNC shares. American Funds SMALLCAP World A is the top mutual fund, with 7.09% of its assets in Revance Therapeutics shares.

RVNC Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockRevance Therapeutics78.60%8.52%12.88%
SectorHealthcare Stocks 88.01%8.90%3.09%
IndustryBiotech Stocks 109.70%8.77%-18.47%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock8.57M9.32%$22.01M
Franklin resources6.26M6.81%$16.09M
Vanguard group5.99M6.52%$15.41M
Palo alto investors lp5.26M5.72%$13.51M
Jpmorgan chase2.94M3.20%$7.57M
Stonepine capital management2.80M3.05%$7.20M
Geode capital management2.30M2.50%$5.91M
State street2.28M2.48%$5.87M
Federated hermes2.24M2.43%$5.75M
Nuveen asset management1.06M1.15%$2.71M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Stonepine capital management2.80M6.57%$7.20M
Palo alto investors lp5.26M1.57%$13.51M
Fny investment advisers477.82K0.75%$1.45M
Alphacentric advisors245.00K0.46%$629.65K
Essex woodlands management457.08K0.38%$1.17M
Dcf advisers250.00K0.33%$642.50K
Rice hall james & associates712.07K0.11%$1.83M
Tang capital management400.00K0.10%$1.03M
Rf&l wealth management48.00K0.10%$145.92K
Deltec asset management100.00K0.06%$304.00K

Top Buyers

HolderShares% AssetsChange
Blackrock8.57M0.00%1.25M
Stonepine capital management2.80M6.57%823.66K
Nuveen asset management1.06M0.00%704.02K
Federated hermes2.24M0.01%672.80K
Millennium management756.91K0.00%604.55K

Top Sellers

HolderShares% AssetsChange
Capital world investors---13.94M
Polar capital---3.57M
Barclays37.34K--2.98M
Rubric capital management lp---2.66M
Cibc asset management---1.74M

New Positions

HolderShares% AssetsChangeValue
Exoduspoint capital management, lp441.58K0.01%441.58K$1.14M
Norges bank161.00K0.00%161.00K$413.77K
Deltec asset management100.00K0.06%100.00K$304.00K
Jacobs levy equity management81.58K0.00%81.58K$209.66K
Simplex trading58.12K0.00%58.12K$149.00K

Sold Out

HolderChange
Toronto dominion bank-5.00
Nelson, van denburg & campbell wealth management group-17.00
Central trust-50.00
Assetmark-68.00
Gamma investing-89.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202422219.35%81,913,8280.64%781.00%11428.09%5530.95%
Jun 30, 2024185-8.87%81,390,810-2.08%880.92%88-15.38%42-12.50%
Mar 31, 2024203-6.02%83,118,62015.30%981.42%104-9.57%48-2.04%
Dec 31, 20232162.37%72,091,641-7.09%830.97%11511.65%49-9.26%
Sep 30, 2023211-10.97%77,595,647-5.45%920.91%103-16.94%54-8.47%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
American Funds SMALLCAP World A7.38M7.09%-
American Funds New Economy A6.33M6.08%-3.96K
Capital Group New Economy Comp6.33M6.08%-3.96K
Vanguard Total Stock Mkt Idx Inv2.97M2.84%-
iShares Russell 2000 ETF2.82M2.70%-10.85K
Fidelity Canadian Large Cap Sr B2.45M2.33%-
Franklin Biotechnology Discv A(acc)USD1.95M1.87%-
Arbitrage R1.59M1.53%164.00K
Federated Hermes MDT Small Cap Core IS1.51M1.45%516.10K
Federated Hermes MDT SCC Institutional1.51M1.45%516.10K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 18, 2024Hollander David CMO & Global Therapeutics LeadSell$16.30K
Apr 16, 2024Jordan Erica Chief Commercial OfficerSell$9.10K
Mar 18, 2024Sjuts Dustin S PresidentSell$46.45K
Mar 18, 2024Moxie Dwight CLO & GCSell$40.97K
Mar 18, 2024Schilke Tobin CFOSell$47.20K

Insider Transactions Trends

DateBuySell
2025 Q1--
2024 Q2-1
2024 Q113
2023 Q4--
2023 Q3-5

RVNC Ownership FAQ

Who Owns Revance Therapeutics?

Revance Therapeutics shareholders are primarily institutional investors at 78.60%, followed by 8.52% insiders and 12.88% retail investors. The average institutional ownership in Revance Therapeutics's industry, Biotech Stocks , is 109.70%, which Revance Therapeutics falls below.

Who owns the most shares of Revance Therapeutics?

Revance Therapeutics’s largest shareholders are Blackrock (8.57M shares, 9.32%), Franklin resources (6.26M shares, 6.81%), and Vanguard group (5.99M shares, 6.52%). Together, they hold 22.65% of Revance Therapeutics’s total shares outstanding.

Does Blackrock own Revance Therapeutics?

Yes, BlackRock owns 9.32% of Revance Therapeutics, totaling 8.57M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 22.01M$. In the last quarter, BlackRock increased its holdings by 1.25M shares, a 17.13% change.

Who is Revance Therapeutics’s biggest shareholder by percentage of total assets invested?

Stonepine capital management is Revance Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.57% of its assets in 2.8M Revance Therapeutics shares, valued at 7.2M$.

Who is the top mutual fund holder of Revance Therapeutics shares?

American Funds SMALLCAP World A is the top mutual fund holder of Revance Therapeutics shares, with 7.09% of its total shares outstanding invested in 7.38M Revance Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools